$UTHR just recorded a 13-point jump in its ACCE composite score, moving from 46 to 59 out of 100. That's a meaningful single-session move — most score changes are incremental, so a delta of that size signals a notable shift in at least one of the four underlying subscore categories: growth, value, quality, or momentum.
The stock is currently priced at $548.30, with a market cap of $23.15B. The consensus analyst target sits at $665.23, implying meaningful upside from the current level if that target proves accurate.
What it means
A 13-point composite gain typically reflects improvement across more than one subscore rather than a single dramatic move in isolation. Here's how each dimension could have contributed:
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
Value. With a trailing P/E of 20.2 and a forward P/E of 19.8, $UTHR trades at a relatively modest multiple for a healthcare name with a specialty-drug franchise. If the value subscore was previously dragging the composite down, a reassessment of the stock's price relative to earnings power could account for part of the gain. The forward P/E being slightly below the trailing figure suggests the market expects modest earnings improvement ahead.
Quality. United Therapeutics operates in pulmonary arterial hypertension, a niche with high barriers to entry and limited generic competition on key products. Quality subscores often reflect balance sheet strength, margin profile, and earnings consistency. A reassessment of those factors — even without a new earnings release — can shift the composite.
Momentum. Price and estimate momentum are dynamic inputs. If analyst estimates were revised upward recently, or if the stock's relative price trend improved versus its healthcare peers, the momentum subscore would respond. The gap between the current price of $548.30 and the analyst target of $665.23 is notable, and any narrowing of that gap through upward price movement feeds directly into momentum signals.
Growth. This is the one area where the current data warrants caution. Year-over-year revenue is down 1.6% and year-over-year earnings are down 12.2%. Those are real headwinds. A score improvement despite those figures suggests the other three dimensions are doing the heavy lifting — or that forward-looking growth expectations have improved even as trailing results disappoint.
The composite score of 59 puts $UTHR in solidly neutral-to-positive territory, but it is not yet in the high-conviction range. The trailing earnings decline is a genuine concern and worth watching in the next quarterly report. The score move is encouraging, but the underlying growth metrics need to stabilize before the picture becomes clearly constructive.
For the live price and full subscore breakdown, visit acceinvestments.com/stocks/UTHR.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
